Status:
UNKNOWN
Clinical Trial Comparing the Self-test for Cervicovaginal Sample Versus Samples From Service Provider (Xyto-Ro)
Lead Sponsor:
Hospital General de México Dr. Eduardo Liceaga
Conditions:
Human Papillomavirus (HPV)-Related Cervical Cancer
HPV DNA
Eligibility:
FEMALE
25-64 years
Phase:
NA
Brief Summary
Problem Description When cervical cancer screening is needed, the Pap test (or Pap smears) is still the most common, although there are challenges that continue to prevent effective screening services...
Detailed Description
STUDY POPULATION The target population is patients admitted to HGM Oncology Service for cervical cancer screening through self-sampling and sampling by a service provider. Sample size is 444 valid pat...
Eligibility Criteria
Inclusion
- Signature of informed consent
- Women with an active sex life
- Women 25 to 64 years old
- Patients without hysterectomy, conization of the cervix.
- Patients without radiotherapy treatment, cervical chemotherapy.
- 24 hours before taking the sample, they should not use douches, ovules, lubricants or gels.
Exclusion
- Patients who have not started a sexual life
- Patients with uterine surgery.
- Patients pregnant.
- Patients with vaginal bleeding.
- Patients who have had sexual activity 24 hours prior to taking the sample.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
444 Patients enrolled
Trial Details
Trial ID
NCT04520464
Start Date
October 1 2020
End Date
October 1 2021
Last Update
August 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General de México Eduardo Liceaga
Mexico City, Mexico, 06720